Profiles
Nuri Guven
Nuri Güven
Associate Head Research
Room 2032 , Chemistry Building
Humans, like every other living organism, are made of cells that need energy to survive. Within each human cell are organelles known as mitochondria. Tiny they may be, yet mitochondria produce more than 90 per cent of all the energy our bodies need to function. And so, it’s not surprising that dysfunctional mitochondria are associated with a large number of diseases, from neurodegenerative Alzheimer’s, Parkinson’s and Huntington’s to inflammatory conditions such as inflammatory bowel disease (IBD). Metabolic disorders such as diabetes, and even cancer, can occur when the mitochondria don’t function as they should. As people age, they become more prone to diseases because the mitochondria work less efficiently.
Despite this, at the moment there is just one drug on the market that has a small effect on dysfunctional mitochondria. It is only available in Europe. And, it’s only approved for a single disease so rare that it affects one in 50,000 people…
In contrast, millions of patients worldwide suffer from disorders that show mitochondrial problems, with insufficient treatment options and an astronomical impact on our healthcare systems. For example, by 2023, the global market for ulcerative colitis, a form of IBD, is estimated to reach 7.5 billion. The market for diabetes-induced vision loss, also called diabetic retinopathy, is expected to reach 10 billion by 2025.
Could the microscopic organelles that power our bodies lead us to discover game-changing new drugs?
Associate Professor Nuri Guven is an expert in drug discovery and development. His research is focused on identifying and developing new molecules to protect against mitochondrial dysfunction in order to develop novel drug candidates.
‘What we’re striving for is to identify molecules that can be used in a whole range of diseases,’ explains Associate Professor Guven. ‘Our aim is to restore mitochondrial function in different tissues, which could enable us to combat a wide range of disorders.
‘We have some very interesting molecules and some very encouraging pre-clinical data. In fact, at least in the lab, we can protect the survival of cells when the mitochondria are impaired or dysfunctional.
‘This is so exciting, but we still have to be very careful,’ warns Associate Professor Guven. ‘Lots of drug candidates show promise in the pre-clinical testing stage, but less than one in a hundred ends up working in humans to a reasonable degree.
‘When the first really efficient drug comes to market it really will be a game-changer, because it is likely to be beneficial for a whole range of disorders, not just one.’
Associate Professor Guven collaborates with Associate Professor Smith from the School of Natural Sciences and many other researchers across the College of Health and Medicine.
‘After the chemists make new molecules, we first of all test their activity,’ he explains. ‘When designing drugs, our main questions are do they work, and are they toxic? I test the efficacy and the toxicity, and the results are then used for the design of the next molecules. That way, we try to make the compound better and better over several stages. This is what’s called the Medicinal Chemistry Program.’
During previous biomedical research, Associate Professor Guven liaised with many patients, which was the inspiration for his career. ‘When you’re speaking to someone with a rare disease and there are no drugs available to them… well, it brings home the good that comes from biomedical research,’ he says.
‘I realised that if I wanted to do anything about it, I had to move away from basic research and into drug discovery. Some of these classic mitochondrial diseases are so rare that the chance of a company developing an effective drug to combat them is negligible.
‘If we can find a drug that works in one of the larger diseases, once it’s on the market, doctors can potentially prescribe it to patients suffering from rare indications. This is a realistic scenario. The “repurposing” of drugs is an effective way of treating patients suffering from diseases for which there are no available drugs at this stage,’ says Associate Professor Guven.
‘It’s a very long process. We could have the best drug in the world, but if it’s not patented and our research isn’t funded, it won’t make it to market. At the end of the day, I want to see drugs reach the market and help patients.’
Currently, Associate Prof Güven acts as Associate Head (Research) for the School of Pharmacy and Pharmacology at UTAS. Before joining UTAS in 2012, where he briefly acted as Deputy Head (School of Pharmacy), Assoc Prof Güven directed the pre-clinical research department at Santhera Pharmaceuticals (Liestal, Switzerland, 2008-2012), where he led several drug discovery projects around novel treatments for neuromuscular disorders and in the field of cancer cachexia. From 2001-2008 he was Senior Research Officer at the Queensland Institute of Medical Research (QIMR, Brisbane, Australia), in the DNA damage and repair field, where he specialized in recessive ataxia syndromes, p53, oxidative stress-induced malignancy and animal models. During this time he was chief investigator on 2 NHMRC and 2 Queensland Cancer Fund applications and attracted US funding for his pharmaceutical work in a neurodegenerative mouse model as CIA. He worked on an industry-project at the University of Tübingen (Department of Radiationoncology, Germany 1999-2002) to identify the active component of a radioprotective drug. His PhD was awarded in 1998 from the University of Konstanz (Germany) in the area of drug discovery in radiation-oncology.
Biography
Assoc Prof Gueven joined UTAS in April 2012, where he acted as Deputy Head (School of Pharmacy) and then Associate Deputy Head (School of Medicine, Division of Pharmacy). Previously he directed the pre-clinical research department at Santhera Pharmaceuticals (Liestal, Switzerland, 2008-2012), where he led several drug discovery projects around novel treatments for neuromuscular disorders and in the field of cancer cachexia. From 2001-2008 he was Senior Research Officer at the Queensland Institute of Medical Research (QIMR, Brisbane, Australia), in the DNA damage and repair field, where he specialized in recessive ataxia syndromes, p53, oxidative stress-induced malignancy and animal models. During this time he was chief investigator on 2 NHMRC and 2 Queensland Cancer Fund applications and attracted US funding for his pharmaceutical work in a cancer mouse model as CIA. He worked on an industry-project at the University of Tübingen (Department of Radiationoncology, Germany 1999-2002) to identify the active component of a radioprotective drug. His PhD was awarded in 1998 from the University of Konstanz (Germany) in the area of drug discovery in radiation-oncology.
Career summary
Qualifications
- PhD, University of Konstanz and University of Tübingen, Germany (1998) Thesis: Radiation-induced signal transduction and radioprotective activity of the Bowman-Birk Protease Inhibitor
- Masters, University of Konstanz, Germany (1994)
Languages (other than English)
German
Memberships
Professional practice
- NIH DNA Repair Special Interest Group
- Associate Investigator of the Australian Research Council (ARC) Centre of Excellence for Free Radical Chemistry and Biotechnology
- Member of the scientific research advisory committee of the Royal Hobart Hospital Research Foundations (RHHRF) and the Erica Bell Foundation
- Editorial Board Member: PLOS ONE and J Pharmaceutics & Pharmacology
Administrative expertise
Associate Prof Güven previously managed multiple drug discovery projects in academic and commercial settings where he was responsible for line management of multidisciplinary teams (i.e. screening, PK/PD, ADME, cell biology, in vivo models, molecular biology, exploratory, in and out-licencing). In addition, he generated documents and presentations for regulatory bodies (EMA/FDA) incl. the participation in interviews and membership on a drug safety committee. Currently he manages several research projects around drug discovery and toxicity for multiple indications. He also designed and established lab infrastructure in several academic and commercial institutions (layout, equipment acquisition, lab maintenance, SOP generation, budget control) and has a keen interest and experience to protect scientific discoveries by patent applications.Current administrative positions:
- Associate Head of School (Research) (2020 - )
- Academic Integrity Advisor (2020 - )
- Member of Defense Export Control Committee (2015 - )
- Member of Chemistry Building Safety Committee (2014 - )
Previous administrative positions:
- Deputy Head of School (School of Pharmacy, 2012 - 2013)
- Member of the Faculty of Health Sciences Research Committee (2012 - 2013)
- School of Medicine Research Committee (2014 - 2018)
- Academic Coordinator (Pharmacy) (2018 - 2019)
- UTAS Medical Science Precinct Lab Management Team (2013 - 2018)
Teaching
Drug discovery and development, toxicology, pre-clinical research, food-supplements, how to give a presentation
Teaching responsibility
Nuri is involved in the organisation and lectures in a number of units within the School of Medicine:
- Pharmacy in Health Care (CSA101)
- Medicinal Medicine & Drug Development (CSA225/226/227)
- Pharmacology (CSA230/232/234/308)
- Toxicology (CSA331/332/333)
- The Art & Science of Clinical Trials (CAD303)
- Pharmacy Skills in Practise 4A (CSA457)
- Critical Evaluation of Research Literature (CSA757)
Research Appointments
- Scientific consultant to Santhera Pharmaceuticals (2012 - present)
- Scientific advisory committee Erica Bell Foundation
- Academic Editor: PLOS ONE
- Academic Editor: J Pharmaceutics & Pharmacology
- Additional recent review activity for: NHMRC, Australia; ORIA, Australia; AFM, France, Medical Research Charities Group (MRCG), Ireland; Health Research Board (HRB), Ireland; Action Research, UK
View more on Dr Nuri Guven in WARP
Expertise
Assoc Prof Gueven is a biomedical scientist with an international reputation for drug discovery and development in disorders associated with oxidative stress, energy impairment and malignancies. His current interests lie in drug discovery in the areas of ulcerative colitis, colorectal cancer and metabolic disorders. The collective impact of his contribution is highlighted by numerous worldwide collaborations with clinicians and researchers, invitations to speak at international meetings, invited reviews, patents as well as editorial and refereeing work. He gave the keynote lecture at the Muscular Dystrophy Association of New Zealand (MDA) and Australasian Neuromuscular Network (ANN) Conference 2015 and was also the invited speaker at a specialized Workshop on CoQ10 deficiency disorders and therapy (Naarden, Netherlands 2010). Nuri has also presented his work at more general conferences such as ComBio. The relevance of his applied research to the health of patients is demonstrated by two patent disclosures in 2012, and a novel submitted patent application in 2014 in the field of personalized medicine (undisclosed). He has published in prestigious journals (J Cell Biol, Hum Mol Gen, Cell Death Diff). His work is widely cited (a total of more than 1600 citations) with an average of more than 30 citations/paper and more than 450 citations for the most highly cited paper.
Research Themes
Nuri's work aligns with the University Theme: 'Better Health'. His core expertise is pre-clinical drug discovery in the area of mitochondrial and metabolic disorders, inflammatory bowel disease as well as cancer. His research spans several disease areas from cancer to neurodegeneration and metabolism.
Collaboration
Associate Prof Güven collaborates with scientists and clinicians worldwide with numerous active collaborations in the areas of mitochondrial and neuromuscular disorders and is involved in clinical research around novel treatments for Duchenne Muscular Dystrophy with Dr Fisher (Children's Hospital, Basel, Switzerland) and Dr Rybalka (Victoria University, Melbourne, Australia). Together with Prof King (Wicking Centre, UTAS) and Prof Pfeffer (Deakin University, Australia) he aims to identify and test novel HDAC6 inhibitors to be used in neuromuscular indications. He also collaborates within the University of Tasmania with Dr. Eri (School of Health Sciences) to identifiy novel therapeutics against inflammatory bowel diseases, with Dr. Smith (School of Chemistry) on the development of novel short chain quinones for the treatment of mitochondrial dysfunction, with Dr. Azimi on novel treatment strategies against medullablastoma and Dr Caruso on a molecule to reduce food intake, just to name a few. In addition, he works with commercial entities such as Marinova Pty (Cambridge, TAS, Australia) and Martha Jane Medical (Australia) to evaluate their products in different pre-clinical models of disease.
Awards
- Kevin Cahill Award (2015) for the most interesting or innovative research in the field of Vision Sciences
Current projects
- Development of short chain quinones for the treatment of mitochondrial dysfunction
- Identification of drugs that affect mitochondrial function
- Identification of drugs and compounds to increase HSP70 expression
- Regulation of Lin28A expression
Fields of Research
- Pharmaceutical sciences (321405)
- Signal transduction (310111)
- Basic pharmacology (321401)
- Pharmacology and pharmaceutical sciences (321499)
- Clinical pharmacology and therapeutics (321402)
- Neurology and neuromuscular diseases (320905)
- Ophthalmology (321201)
- Biologically active molecules (340401)
- Gastroenterology and hepatology (320209)
- Biochemistry and cell biology (310199)
- Systems physiology (320803)
- Organic chemical synthesis (340503)
- Separation science (340109)
- Central nervous system (320903)
- Cell development, proliferation and death (310102)
- Clinical sciences (320299)
- Medical biochemistry and metabolomics (320599)
- Medicinal and biomolecular chemistry (340499)
- Sensory systems (320907)
- Proteins and peptides (340407)
- Animal physiology - systems (310910)
- Cellular nervous system (320902)
- Molecular targets (321108)
- Metabolic medicine (320507)
- Traditional, complementary and integrative medicine (420899)
- Motor control (420703)
- Animal cell and molecular biology (310902)
- Genetic immunology (310507)
- Analytical chemistry (340199)
- Neurosciences (320999)
- Enzymes (310106)
- Toxicology (incl. clinical toxicology) (321407)
- Health services and systems (420399)
- Analytical biochemistry (310101)
- Allergy (320401)
- Gene and molecular therapy (320601)
- Medical biochemistry - proteins and peptides (incl. medical proteomics) (320506)
- Cancer therapy (excl. chemotherapy and radiation therapy) (321104)
- Cancer cell biology (321101)
- Cell neurochemistry (310104)
- Optical technology (321202)
- Cardiology (incl. cardiovascular diseases) (320101)
- Peripheral nervous system (320906)
- Behavioural neuroscience (520202)
- Autonomic nervous system (320901)
- Aquaculture (300501)
- Traditional Chinese medicine and treatments (420803)
- Ophthalmology and optometry (321299)
- Cellular immunology (320404)
- Pharmacogenomics (321406)
- Oncology and carcinogenesis (321199)
- Cell physiology (320801)
- Animal physiology - cell (310909)
- Tumour immunology (320409)
- Epigenetics (incl. genome methylation and epigenomics) (310504)
- Immunology (320499)
- Cell metabolism (310103)
Research Objectives
- Clinical health (200199)
- Expanding knowledge in the biological sciences (280102)
- Expanding knowledge in the health sciences (280112)
- Other health (209999)
- Human pharmaceutical products (240899)
- Public health (excl. specific population health) (200499)
- Treatment of human diseases and conditions (200105)
- Human pharmaceutical treatments (240803)
- Expanding knowledge in the chemical sciences (280105)
- Expanding knowledge in the biomedical and clinical sciences (280103)
- Behaviour and health (200401)
- Preventive medicine (200412)
- Other environmental management (189999)
- Efficacy of medications (200102)
- Fisheries - aquaculture (100299)
- Aboriginal and Torres Strait Islander determinants of health (210301)
Publications
Associate Prof Güven is widely published with about 50% of publications as first or last author. He is frequently asked to supply invited reviews. On average he has published 5 papers per year over the last 5 years (excluding patents). Nuri's publications are highly cited (>2500) with a h-index of 26 (Scopus) and the highest cited paper receiving more than 500 citations. He delivered a seminal paper on the activation of the tumour suppressor p53 in Cell Death and Differentiation and was author on the first paper describing molecular activity of short chain quinones that make them useful to treat mitochondrial disease. He published two international patents disclosed in 2012 from his work in the pharmaceutical industry, which are now part of the essential IP portfolio of the company. In addition, he authored one Australian provisional patent application in 2014 and an international patent in 2018 with ongoing licence negotiations .
Total publications
100
Journal Article
(79 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2021 | Daniel A, Premilovac D, Foa L, Feng ZK, Shah K, et al., 'Novel short-chain quinones to treat vision loss in a rat model of diabetic retinopathy', International Journal of Molecular Sciences, 22, (3) Article 1016. ISSN 1422-0067 (2021) [Refereed Article] DOI: 10.3390/ijms22031016 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Daniel A; Premilovac D; Foa L; Feng ZK; Shah K; Woolley KL; Bye N; Smith Jason Alfred | |
| 2021 | Feng ZK, Nadikudi M, Woolley KL, Hemasa AL, Chear S, et al., 'Bioactivity profiles of cytoprotective short-chain quinones', Molecules, 26, (5) Article 1382. ISSN 1420-3049 (2021) [Refereed Article] DOI: 10.3390/molecules26051382 [eCite] [Details] Citations: Scopus - 1 Co-authors: Feng ZK; Nadikudi M; Woolley KL; Smith JA | |
| 2021 | Gueven N, Ravishankar P, Eri RD, Rybalka E, 'Idebenone: when an antioxidant is not an antioxidant', Redox Biology, 38 Article 101812. ISSN 2213-2317 (2021) [Refereed Article] DOI: 10.1016/j.redox.2020.101812 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Ravishankar P; Eri RD | |
| 2021 | Hearn KN, Ashton TD, Acharya R, Feng Z, Gueven N, et al., 'Direct amidation to access 3-Amido-1,8-naphthalimides including fluorescent scriptaid analogues as HDAC inhibitors', Cells, 10 pp. 1-10. ISSN 2073-4409 (2021) [Refereed Article] DOI: 10.3390/cells10061505 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 Co-authors: Feng Z | |
| 2021 | Ishaq M, Tran D, Wu Y, Nowak K, Deans BJ, et al., 'Asperuloside enhances taste perception and prevents weight gain in high-fat fed mice', Frontiers in Endocrinology, 12 pp. 1-11. ISSN 1664-2392 (2021) [Refereed Article] DOI: 10.3389/fendo.2021.615446 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 Co-authors: Ishaq M; Wu Y; Deans BJ; Southam B; Vicenzi S; Randall C; Yang C; Tan E; Ahmad T; Shastri M; Bleasel M; Scowen P; Jacobson G; Bissember AC; Smith JA; Eri R; Canales J; Iglesias M; Caruso V | |
| 2021 | Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, et al., 'Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?', Orphanet Journal of Rare Diseases, 16, (1) pp. 1-9. ISSN 1750-1172 (2021) [Refereed Article] DOI: 10.1186/s13023-021-01758-9 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 | |
| 2021 | Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, et al., 'Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy', Redox Biology Article 101803. ISSN 2213-2317 (2021) [Refereed Article] DOI: 10.1016/j.redox.2020.101803 [eCite] [Details] Citations: Scopus - 10Web of Science - 10 | |
| 2021 | Paul AK, Gueven N, Dietis N, 'Profiling the effects of repetitive morphine administration on motor behavior in rats', Molecules, 26, (4) pp. 1-14. ISSN 1420-3049 (2021) [Refereed Article] DOI: 10.3390/molecules26144355 [eCite] [Details] Citations: Scopus - 2Web of Science - 1 Co-authors: Paul AK | |
| 2021 | Shastri S, Shinde T, Woolley KL, Smith JA, Gueven N, et al., 'Short-chain naphthoquinone protects against both acute and spontaneous chronic murine colitis by alleviating inflammatory responses', Frontiers in Pharmacology, 12 pp. 1-16. ISSN 1663-9812 (2021) [Refereed Article] DOI: 10.3389/fphar.2021.709973 [eCite] [Details] Co-authors: Woolley KL; Smith JA; Eri R | |
| 2020 | Feng Z, Sedeeq M, Daniel A, Corban M, Woolley KL, et al., 'Comparative in vitro toxicology of novel cytoprotective short-chain naphthoquinones', Pharmaceuticals, 13, (8) pp. 1-20. ISSN 1424-8247 (2020) [Refereed Article] DOI: 10.3390/ph13080184 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Feng Z; Sedeeq M; Daniel A; Corban M; Woolley KL; Condie R; Azimi I; Smith JA | |
| 2020 | Feng Z, Smith JA, Gueven N, Quirino JP, 'Metabolic stability of new mito-protective short-chain naphthoquinones', Pharmaceuticals, 13, (2) pp. 1-12. ISSN 1424-8247 (2020) [Refereed Article] DOI: 10.3390/ph13020029 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Feng Z; Smith JA; Quirino JP | |
| 2020 | Guven N, Spring KJ, Holmes S, Ahuja K, Eri R, et al., 'Micro RNA expression after ingestion of fucoidan; a clinical study', Marine Drugs, 18, (3) pp. 1-11. ISSN 1660-3397 (2020) [Refereed Article] DOI: 10.3390/md18030143 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Holmes S; Ahuja K; Eri R | |
| 2020 | Rudebeck EE, Cox RP, Bell TDM, Acharya R, Feng Z, et al., 'Mixed alkoxy/hydroxy 1,8-naphthalimides: expanded fluorescence colour palette and in vitro bioactivity', Chemical Communications, 56, (50) pp. 6866-6869. ISSN 1359-7345 (2020) [Refereed Article] DOI: 10.1039/d0cc01251c [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Feng Z | |
| 2020 | Sedeeq M, Maklad A, Guven N, Azimi I, 'Development of a high-throughput agar colony formation assay to identify drug candidates against medulloblastoma', Pharmaceuticals, 13, (11) Article 368. ISSN 1424-8247 (2020) [Refereed Article] DOI: 10.3390/ph13110368 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 Co-authors: Sedeeq M; Maklad A; Azimi I | |
| 2020 | Shastri S, Shinde T, Perera AP, Gueven N, Eri R, 'Idebenone protects against spontaneous chronic murine colitis by alleviating endoplasmic reticulum stress and inflammatory response', Biomedicines, 8, (10) Article 384. ISSN 2227-9059 (2020) [Refereed Article] DOI: 10.3390/biomedicines8100384 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Perera AP; Eri R | |
| 2020 | Shastri S, Shinde T, Sohal SS, Gueven N, Eri R, 'Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms', International Journal of Molecular Sciences, 21, (2) pp. 1-21. ISSN 1422-0067 (2020) [Refereed Article] DOI: 10.3390/ijms21020484 [eCite] [Details] Citations: Scopus - 8Web of Science - 8 Co-authors: Sohal SS; Eri R | |
| 2020 | Timpani CA, Goodman CA, Stathis CG, White JD, Mamchaoui K, et al., 'Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy', Scientific reports, 10, (1) Article 1125. ISSN 2045-2322 (2020) [Refereed Article] DOI: 10.1038/s41598-020-57610-w [eCite] [Details] Citations: Scopus - 9Web of Science - 8 | |
| 2019 | Corban M, Ambrose M, Pagnon J, Stringer D, Karpiniec S, et al., 'Pathway analysis of fucoidan activity using a yeast gene deletion library screen', Marine drugs, 17, (1) Article 54. ISSN 1660-3397 (2019) [Refereed Article] DOI: 10.3390/md17010054 [eCite] [Details] Citations: Scopus - 5Web of Science - 6 Co-authors: Corban M; Ambrose M; Eri R; Fitton JH | |
| 2019 | Hafner P, Bonati U, Klein A, Rubino D, Gocheva V, et al., 'Effect of Combination L-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial', JAMA Network Open, 2, (10) Article e1914171. ISSN 2574-3805 (2019) [Refereed Article] DOI: 10.1001/jamanetworkopen.2019.14171 [eCite] [Details] Citations: Scopus - 11Web of Science - 8 | |
| 2019 | Wilson R, Gundamaraju R, Vemuri R, Angelucci C, Geraghty D, et al., 'Identification of key pro-survival proteins in isolated colonic goblet cells of Winnie, a murine model of spontaneous colitis', Inflammatory Bowel Diseases, 26, (1) pp. 80-92. ISSN 1536-4844 (2019) [Refereed Article] DOI: 10.1093/ibd/izz179 [eCite] [Details] Citations: Scopus - 3Web of Science - 26 Co-authors: Wilson R; Vemuri R; Angelucci C; Geraghty D; Eri RD | |
| 2019 | Woolley KL, Nadikudi M, Koupaei MN, Corban M, McCartney P, et al., 'Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction', MedChemComm, 10, (3) pp. 399-412. ISSN 2040-2511 (2019) [Refereed Article] DOI: 10.1039/c8md00582f [eCite] [Details] Citations: Scopus - 9Web of Science - 10 Co-authors: Woolley KL; Nadikudi M; Corban M; Bissember AC; Lewis TW; Smith JA | |
| 2018 | Chhetri J, King AE, Gueven N, 'Alzheimer's Disease and NQO1: is there a link?', Current Alzheimer Research, 15 pp. 56-66. ISSN 1567-2050 (2018) [Refereed Article] DOI: 10.2174/1567205014666170203095802 [eCite] [Details] Citations: Scopus - 19Web of Science - 16 Co-authors: Chhetri J; King AE | |
| 2018 | Paul AK, Gueven N, Dietis N, 'Data on prolonged morphine-induced antinociception and behavioral inhibition in older rats', Data in Brief, 19 pp. 183-188. ISSN 2352-3409 (2018) [Contribution to Refereed Journal] DOI: 10.1016/j.dib.2018.05.001 [eCite] [Details] Citations: Scopus - 3Web of Science - 2 Co-authors: Dietis N | |
| 2018 | Paul AK, Gueven N, Dietis N, 'Age-dependent antinociception and behavioral inhibition by morphine', Pharmacology, Biochemistry and Behavior, 168 pp. 8-16. ISSN 0091-3057 (2018) [Refereed Article] DOI: 10.1016/j.pbb.2018.03.003 [eCite] [Details] Citations: Scopus - 4Web of Science - 3 Co-authors: Dietis N | |
| 2018 | Wanandy T, Wilson R, Gell D, Rose HE, Gueven N, et al., 'Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach', Clinical and Experimental Allergy, 48, (9) pp. 1222-1234. ISSN 1365-2222 (2018) [Refereed Article] DOI: 10.1111/cea.13224 [eCite] [Details] Citations: Scopus - 6Web of Science - 7 Co-authors: Wanandy T; Wilson R; Gell D; Davies NW; Brown SGA | |
| 2017 | Alhusban A, Breadmore MC, Gueven N, Guijt RM, 'Time-Resolved Pharmacological Studies using Automated, Online Monitoring of Five Parallel Suspension Cultures', Scientific Reports, 7 pp. 1-9. ISSN 2045-2322 (2017) [Refereed Article] DOI: 10.1038/s41598-017-10472-1 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Breadmore MC; Guijt RM | |
| 2017 | Cui H, Zhang AJ, McKeage MJ, Nott LM, Geraghty D, et al., 'Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity', Journal of Inorganic Biochemistry, 177 pp. 249-258. ISSN 0162-0134 (2017) [Refereed Article] DOI: 10.1016/j.jinorgbio.2017.04.022 [eCite] [Details] Citations: Scopus - 12Web of Science - 13 Co-authors: Cui H; Nott LM; Geraghty D | |
| 2017 | Deans BJ, Just J, Chhetri J, Burt LK, Smith JN, et al., 'Pressurized hot water extraction as a viable bioprospecting tool: isolation of coumarin natural products from previously unexamined Correa (Rutaceae) species', ChemistrySelect, 2, (8) pp. 2439-2443. ISSN 2365-6549 (2017) [Refereed Article] DOI: 10.1002/slct.201602006 [eCite] [Details] Citations: Scopus - 11Web of Science - 11 Co-authors: Deans BJ; Just J; Chhetri J; Burt LK; Smith JN; Kilah NL; Bissember AC; Smith JA | |
| 2017 | Gueven N, Nadikudi M, Daniel AO, Chhetri J, 'Targeting mitochondrial function to treat optic neuropathy', Mitochondrion, 36 pp. 7-14. ISSN 1567-7249 (2017) [Refereed Article] DOI: 10.1016/j.mito.2016.07.013 [eCite] [Details] Citations: Scopus - 27Web of Science - 21 Co-authors: Nadikudi M; Daniel AO; Chhetri J | |
| 2017 | Kunde DA, Chong WC, Nerurkar PV, Ahuja KDK, Just J, et al., 'Bitter melon protects against ER stress in LS174T colonic epithelial cells', BMC Alternative Medicine, 17 Article 2. ISSN 1472-6882 (2017) [Refereed Article] DOI: 10.1186/s12906-016-1522-1 [eCite] [Details] Citations: Scopus - 10Web of Science - 10 Co-authors: Kunde DA; Chong WC; Ahuja KDK; Just J; Smith JA; Eri RD | |
| 2017 | Paul AK, Guven N, Dietis N, 'Morphine dosing strategy plays a key role in the generation and duration of the produced antinociceptive tolerance', Neuropharmacology, 121 pp. 158-166. ISSN 0028-3908 (2017) [Refereed Article] DOI: 10.1016/j.neuropharm.2017.04.034 [eCite] [Details] Citations: Scopus - 9Web of Science - 7 Co-authors: Dietis N | |
| 2017 | Wanandy T, Dwyer HE, McLean L, Davies NW, Nichols D, et al., 'Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnosis of allergen sensitization and in allergen immunotherapy', Clinical and Experimental Allergy, 47, (11) pp. 1478-1490. ISSN 1365-2222 (2017) [Refereed Article] DOI: 10.1111/cea.12987 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Wanandy T; Dwyer HE; McLean L; Davies NW; Nichols D; Brown SGA; Wiese MD | |
| 2016 | Alhusban AA, Breadmore MC, Gueven N, Guijt RM, 'Capillary electrophoresis for automated on-line monitoring of suspension cultures: Correlating cell density, nutrients and metabolites in near real-time', Analytica Chimica Acta, 920 pp. 94-101. ISSN 0003-2670 (2016) [Refereed Article] DOI: 10.1016/j.aca.2016.03.034 [eCite] [Details] Citations: Scopus - 16Web of Science - 14 Co-authors: Breadmore MC; Guijt RM | |
| 2016 | Chhetri J, Gueven N, 'Targeting mitochondrial function to protect against vision loss', Expert Opinion on Emerging Therapeutic Targets, 20, (6) pp. 721-36. ISSN 1472-8222 (2016) [Refereed Article] DOI: 10.1517/14728222.2015.1134489 [eCite] [Details] Citations: Scopus - 10Web of Science - 8 Co-authors: Chhetri J | |
| 2016 | Gueven N, 'Idebenone for Leber's hereditary optic neuropathy', Drugs of today, 52, (3) pp. 173-181. ISSN 1699-3993 (2016) [Refereed Article] DOI: 10.1358/dot.2016.52.3.2463564 [eCite] [Details] Citations: Scopus - 24Web of Science - 18 | |
| 2016 | Hafner P, Bonati U, Erne B, Schmid M, Rubino D, et al., 'Improved muscle function in Duchenne muscular dystrophy through L-arginine and metformin: an investigator-initiated, open-label, single-center, proof-of-concept-study', PLoS One, 11, (1) Article e0147634. ISSN 1932-6203 (2016) [Refereed Article] DOI: 10.1371/journal.pone.0147634 [eCite] [Details] Citations: Scopus - 36Web of Science - 34 | |
| 2016 | Hafner P, Bonati U, Rubino D, Gocheva V, Zumbrunn T, et al., 'Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial', Trials, 17, (1) Article 389. ISSN 1745-6215 (2016) [Refereed Article] DOI: 10.1186/s13063-016-1503-1 [eCite] [Details] Citations: Scopus - 24Web of Science - 21 | |
| 2016 | Randall-Demllo S, Fernando R, Brain T, Sohal SS, Cook AL, et al., 'Characterisation of colonic dysplasia-like epithelial atypia in murine colitis', World Journal of Gastroenterology, 22, (37) pp. 8334-8348. ISSN 1007-9327 (2016) [Refereed Article] DOI: 10.3748/wjg.v22.i37.8334 [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Randall-Demllo S; Sohal SS; Cook AL; Kunde D; Eri R | |
| 2016 | Yin X, Guven N, Dietis N, 'Stress-based animal models of depression: Do we actually know what we are doing?', Brain research, 1652 pp. 30-42. ISSN 0006-8993 (2016) [Refereed Article] DOI: 10.1016/j.brainres.2016.09.027 [eCite] [Details] Citations: Scopus - 46Web of Science - 42 Co-authors: Yin X; Dietis N | |
| 2015 | Buyse GM, Gueven N, McDonald CM, 'Idebenone as a novel therapeutic approach for Duchenne Muscular Dystrophy', European Neurological Review, 10, (2) pp. 189-94. ISSN 1758-3837 (2015) [Refereed Article] DOI: 10.17925/ENR.2015.10.02.189 [eCite] [Details] Citations: Scopus - 3 | |
| 2015 | Guven N, Woolley K, Smith J, 'Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10', Redox Biology, 4 pp. 289-295. ISSN 2213-2317 (2015) [Refereed Article] DOI: 10.1016/j.redox.2015.01.009 [eCite] [Details] Citations: Scopus - 63Web of Science - 61 Co-authors: Woolley K; Smith J | |
| 2015 | Kijas AW, Lim YC, Bolderson E, Cerosaletti K, Gatei M, et al., 'ATM-dependent phosphorylation of MRE11 controls extent of resection during homology directed repair by signalling through Exonuclease 1', Nucleic Acids Research, 43, (17) pp. 8352-8367. ISSN 0305-1048 (2015) [Refereed Article] DOI: 10.1093/nar/gkv754 [eCite] [Details] Citations: Scopus - 34Web of Science - 33 | |
| 2015 | Lean QY, Eri RD, Fitton JH, Patel RP, Gueven N, 'Fucoidan extracts ameliorate acute colitis', PLoS One, 10, (6) Article e0128453. ISSN 1932-6203 (2015) [Refereed Article] DOI: 10.1371/journal.pone.0128453 [eCite] [Details] Citations: Scopus - 50Web of Science - 44 Co-authors: Lean QY; Eri RD; Patel RP | |
| 2015 | Lean QY, Eri RD, Randall-Demllo S, Sohal SS, Stewart N, et al., 'Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses', PLoS One, 10, (7) Article e0134259. ISSN 1932-6203 (2015) [Refereed Article] DOI: 10.1371/journal.pone.0134259 [eCite] [Details] Citations: Scopus - 17Web of Science - 13 Co-authors: Lean QY; Eri RD; Randall-Demllo S; Sohal SS; Stewart N; Peterson GM; Patel RP | |
| 2015 | Lean QY, Gueven N, Eri RD, Bhatia R, Sohal SS, et al., 'Heparins in ulcerative colitis: proposed and potential reasons for inconsistent clinical outcomes', Expert Review of Clinical Pharmacology, 8, (6) pp. 795-811. ISSN 1751-2433 (2015) [Refereed Article] DOI: 10.1586/17512433.2015.1082425 [eCite] [Details] Citations: Scopus - 9Web of Science - 9 Co-authors: Lean QY; Eri RD; Sohal SS; Stewart N; Peterson GM; Patel RP | |
| 2015 | Shastri MD, Stewart N, Eapen M, Peterson GM, Zaidi STR, et al., 'Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics', PLoS One, 10, (3) Article e0118798. ISSN 1932-6203 (2015) [Refereed Article] DOI: 10.1371/journal.pone.0118798 [eCite] [Details] Citations: Scopus - 17Web of Science - 16 Co-authors: Shastri MD; Stewart N; Eapen M; Peterson GM; Zaidi STR; Sohal SS; Patel RP | |
| 2015 | Shastri MD, Stewart N, Horne J, Peterson GM, Gueven N, et al., 'In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin', PLoS One, 10, (5) Article e0126763. ISSN 1932-6203 (2015) [Refereed Article] DOI: 10.1371/journal.pone.0126763 [eCite] [Details] Citations: Scopus - 28Web of Science - 26 Co-authors: Shastri MD; Stewart N; Horne J; Peterson GM; Sohal SS; Patel RP | |
| 2015 | Shastri MD, Stewart N, Horne J, Zaidi STR, Sohal SS, et al., 'Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals', PLoS One, 10, (6) Article e0128803. ISSN 1932-6203 (2015) [Refereed Article] DOI: 10.1371/journal.pone.0128803 [eCite] [Details] Citations: Scopus - 21Web of Science - 19 Co-authors: Shastri MD; Stewart N; Horne J; Zaidi STR; Sohal SS; Peterson GM; Korner H; Patel RP | |
| 2015 | Wanandy T, Guven N, Davies NW, Brown SGA, Wiese MD, 'Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula', Toxicon, 98 pp. 54-61. ISSN 0041-0101 (2015) [Refereed Article] DOI: 10.1016/j.toxicon.2015.02.013 [eCite] [Details] Citations: Scopus - 22Web of Science - 23 Co-authors: Wanandy T; Davies NW | |
| 2015 | Yin X, Guven N, Dietis N, 'Opioids in depression: not quite there yet', UK Journal of Pharmaceutical and Biosciences, 3, (1) pp. 12-17. ISSN 2347-9442 (2015) [Refereed Article] Co-authors: Yin X; Dietis N | |
| 2014 | Alhusban AA, Gaudry AJ, Breadmore MC, Gueven N, Guijt RM, 'On-line sequential injection-capillary electrophoresis for near-real-time monitoring of extracellular lactate in cell culture flasks', Journal of Chromatography A, 1323 pp. 157-162. ISSN 0021-9673 (2014) [Refereed Article] DOI: 10.1016/j.chroma.2013.11.006 [eCite] [Details] Citations: Scopus - 23Web of Science - 21 Co-authors: Breadmore MC; Guijt RM | |
| 2014 | Chhetri J, Jacobson G, Gueven N, 'Zebrafish - on the move towards ophthalmological research', Eye, 28 pp. 367-380. ISSN 0950-222X (2014) [Refereed Article] DOI: 10.1038/eye.2014.19 [eCite] [Details] Citations: Scopus - 73Web of Science - 71 Co-authors: Chhetri J; Jacobson G | |
| 2014 | Lean QY, Patel RP, Stewart N, Sohal SS, Guven N, 'Identification of pro-and anti-proliferative oligosaccharides of heparins', Integrative Biology, 6, (1) pp. 90 - 99. ISSN 0974-2816 (2014) [Refereed Article] DOI: 10.1039/c3ib40206a [eCite] [Details] Citations: Scopus - 13Web of Science - 12 Co-authors: Lean QY; Patel RP; Stewart N; Sohal SS | |
| 2014 | Paul A, Guven N, Dietis N, 'Opioid receptor-dependent modulation of insulin-release in pancreatic beta-cells', UK Journal of Pharmaceutical and Biosciences, 2, (6) pp. 22-31. ISSN 2347-9442 (2014) [Refereed Article] Co-authors: Dietis N | |
| 2013 | Shabala L, Walker EJ, Eklund A, Randall-Demllo S, Shabala S, et al., 'Exposure of colonic epithelial cells to oxidative and endoplasmic reticulum stress causes rapid potassium efflux and calcium influx', Cell Biochemistry and Function, 31, (7) pp. 603-611. ISSN 1099-0844 (2013) [Refereed Article] DOI: 10.1002/cbf.2946 [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Shabala L; Walker EJ; Randall-Demllo S; Shabala S; Cook AL; Eri RD | |
| 2012 | Erb M, Hoffmann-Enger B, Deppe H, Soedberdt M, Haefeli RH, et al., 'Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I', PLoS One, 7, (4) Article e36153. ISSN 1932-6203 (2012) [Refereed Article] DOI: 10.1371/journal.pone.0036153 [eCite] [Details] Citations: Scopus - 64Web of Science - 55 | |
| 2012 | Heitz FD, Erb M, Anklin C, Robay D, Pernet V, et al., 'Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy', PLoS One, 7, (9) Article e45182. ISSN 1932-6203 (2012) [Refereed Article] DOI: 10.1371/journal.pone.0045182 [eCite] [Details] Citations: Scopus - 71Web of Science - 66 | |
| 2012 | Murad NAA, Cullen JK, McKenzie M, Ryan MT, Thorburn D, et al., 'Mitochondrial dysfunction in a novel form of autosomal recessive ataxia', Mitochondrion, 13, (3) pp. 235-245. ISSN 1872-8278 (2012) [Refereed Article] DOI: 10.1016/j.mito.2012.11.006 [eCite] [Details] Citations: Scopus - 4Web of Science - 5 | |
| 2011 | Brown JA, Roberts TL, Richards R, Woods R, Birrell G, et al., 'A Novel Role for hSMG-1 in Stress Granule Formation', Molecular and Cellular Biology, 31, (2) pp. 4417 - 4429. ISSN 0270-7306 (2011) [Refereed Article] DOI: 10.1128/MCB.05987-11 [eCite] [Details] Citations: Scopus - 31Web of Science - 31 | |
| 2011 | Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, et al., 'The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia', Journal of Cachexia, Sarcopenia and Muscle, 2, (3) pp. 163-174. ISSN 2190-5991 (2011) [Refereed Article] DOI: 10.1007/s13539-011-0039-1 [eCite] [Details] Citations: Scopus - 38Web of Science - 36 | |
| 2011 | Gatei M, Jakob B, Chen P, Kijas AW, Becherel OJ, et al., 'ATM-Dependent Phosphorylation of RAD50 regulates DNA repair and cell cycle control', Journal of Biological Chemistry, 286, (36) pp. 31542-31556. ISSN 1083-351X (2011) [Refereed Article] DOI: 10.1074/jbc.M111.258152 [eCite] [Details] Citations: Scopus - 55Web of Science - 53 | |
| 2011 | Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, et al., 'NQO1-Dependent Redox Cycling of Idebenone: effects on cellular Redox potential and energy levels', PLoS One, 6, (3) Article e17963. ISSN 1932-6203 (2011) [Refereed Article] DOI: 10.1371/journal.pone.0017963 [eCite] [Details] Citations: Scopus - 126Web of Science - 117 | |
| 2010 | Craig AL, Holcakova J, Finlan LE, Nekulova M, Hrstka R, et al., 'DeltaNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation', Molecular Cancer, 9, (195) pp. 1-13. ISSN 1476-4598 (2010) [Refereed Article] DOI: 10.1186/1476-4598-9-195 [eCite] [Details] Citations: Scopus - 29Web of Science - 27 | |
| 2010 | Morrow BJ, Keddie DJ, Gueven N, Lavin MF, Bottle SE, 'A novel profluorescent nitroxide as a sensitive probe for the cellular redox environment', Free Radical Biology & Medicine, 49, (1) pp. 67-76. ISSN 1873-4596 (2010) [Refereed Article] DOI: 10.1016/j.freeradbiomed.2010.03.019 [eCite] [Details] Citations: Scopus - 53Web of Science - 54 | |
| 2009 | Becherel OJ, Jakob B, Cherry AL, Guven N, Fusser M, et al., 'CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response', Nucleic Acids Research pp. 1-15. ISSN 1362-4962 (2009) [Refereed Article] DOI: 10.1093/nar/gkp1149 [eCite] [Details] Citations: Scopus - 44Web of Science - 43 | |
| 2007 | Gueven N, Becherel OJ, Howe O, Chen P, Haince J-F, et al., 'A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance', Cell Death and Differentiation, 14, (6) pp. 1149-1161. ISSN 1350-9047 (2007) [Refereed Article] DOI: 10.1038/sj.cdd.4402116 [eCite] [Details] Citations: Scopus - 14Web of Science - 12 | |
| 2007 | Gueven N, Chen P, Nakamura J, Becherel OJ, Kijas AW, et al., 'A subgroup of spinocerebellar ataxias defective in DNA damage responses', Neuroscience: An International Journal, 145, (4) pp. 1418-1425. ISSN 0306-4522 (2007) [Refereed Article] DOI: 10.1016/j.neuroscience.2006.12.010 [eCite] [Details] Citations: Scopus - 45Web of Science - 43 | |
| 2007 | Suraweera A, Becherel OJ, Chen P, Rundle N, Woods R, et al., 'Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage', The Journal of Cell Biology, 177, (6) pp. 969-979. ISSN 1540-8140 (2007) [Refereed Article] DOI: 10.1083/jcb.200701042 [eCite] [Details] Citations: Scopus - 138Web of Science - 137 | |
| 2006 | Gueven N, Luff J, Peng C, Hosokawa K, Bottle SE, et al., 'Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant', Free Radical Biology and Medicine, 41, (6) pp. 992-1000. ISSN 0891-5849 (2006) [Refereed Article] DOI: 10.1016/j.freeradbiomed.2006.06.018 [eCite] [Details] Citations: Scopus - 68Web of Science - 62 | |
| 2006 | Lavin MF, Guven N, 'The complexity of p53 stabilization and activation', Cell Death and Differentiation, 13, (6) pp. 941-950. ISSN 1350-9047 (2006) [Refereed Article] DOI: 10.1038/sj.cdd.4401925 [eCite] [Details] Citations: Scopus - 512Web of Science - 496 | |
| 2005 | Truman J-P, Gueven N, Lavin M, Leibel S, Kolesnick R, et al., 'Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis', Journal of Biological Chemistry, 280, (24) pp. 23262-23272. ISSN 0021-9258 (2005) [Refereed Article] DOI: 10.1074/jbc.M503701200 [eCite] [Details] Citations: Scopus - 46Web of Science - 46 | |
| 2004 | Gueven N, Becherel OJ, Kijas AW, Chen P, Howe O, et al., 'Aprataxin, a novel protein that protects against genotoxic stress', Human Molecular Genetics, 13, (10) pp. 1081-1093. ISSN 0964-6906 (2004) [Refereed Article] DOI: 10.1093/hmg/ddh122 [eCite] [Details] Citations: Scopus - 136Web of Science - 129 | |
| 2004 | Lavin MF, Scott SP, Kozlov S, Gueven N, 'Analyzing the regulation and function of ATM', Methods in Molecular Biology, 281 pp. 163-178. ISSN 1064-3745 (2004) [Refereed Article] | |
| 2003 | Glover D, Little JB, Lavin MF, Gueven N, 'Low dose ionizing radiation-induced activation of connexin 43 expression', International Journal of Radiation Biology, 79, (12) pp. 955-964. ISSN 0955-3002 (2003) [Refereed Article] DOI: 10.1080/09553000310001632895 [eCite] [Details] Citations: Scopus - 32Web of Science - 31 | |
| 2003 | Gueven N, Keating K, Fukao T, Loeffler H, Kondo N, et al., 'Site-directed mutagenesis of the ATM promoter: Consequences for response to proliferation and ionizing radiation', Genes, Chromosomes and Cancer, 38, (2) pp. 157-167. ISSN 1045-2257 (2003) [Refereed Article] DOI: 10.1002/gcc.10261 [eCite] [Details] Citations: Scopus - 26Web of Science - 26 | |
| 2003 | Kozlov S, Gueven N, Keating K, Ramsay J, Lavin MF, 'ATP activates ataxia-telangiectasia mutated (ATM) in vitro. Importance of autophosphorylation', Journal of Biological Chemistry, 278, (11) pp. 9309-9317. ISSN 0021-9258 (2003) [Refereed Article] DOI: 10.1074/jbc.M300003200 [eCite] [Details] Citations: Scopus - 74Web of Science - 72 | |
| 2002 | Beamish H, Kedar P, Kaneko H, Chen P, Fukao T, et al., 'Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM', Journal of Biological Chemistry, 277, (34) pp. 30515-30523. ISSN 0021-9258 (2002) [Refereed Article] DOI: 10.1074/jbc.M203801200 [eCite] [Details] Citations: Scopus - 102Web of Science - 99 | |
| 2001 | Dittmann KH, Gueven N, Mayer C, Rodemann HP, 'Characterization of the amino acids essential for the photo- and radioprotective effects of a Bowman-Birk protease inhibitor -derived nonapeptide', Protein Engineering, 14, (3) pp. 157-160. ISSN 0269-2139 (2001) [Refereed Article] DOI: 10.1093/protein/14.3.157 [eCite] [Details] Citations: Web of Science - 19 | |
| 2001 | Gueven N, Keating KE, Chen P, Fukao T, Khanna KK, et al., 'Epidermal Growth Factor Sensitizes Cells to Ionizing Radiation by Down-regulating Protein Mutated in Ataxia-Telangiectasia', Journal of Biological Chemistry, 276, (12) pp. 8884-8891. ISSN 0021-9258 (2001) [Refereed Article] DOI: 10.1074/jbc.M006190200 [eCite] [Details] Citations: Scopus - 47Web of Science - 43 |
Chapter in Book
(1 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2016 | Lean QY, Gueven N, Eri RD, Peterson GM, Patel RP, 'Non-Anticoagulant Oligosaccharides of Enoxaparin Relieve Chemical-Induced Acute Colitis', Advances in Medicine and Biology, Nova Science Publishers, LV Berhardt (ed), United States, pp. 87-104. ISBN 978-1-63483-988-4 (2016) [Research Book Chapter] Co-authors: Lean QY; Eri RD; Peterson GM; Patel RP |
Review
(11 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2021 | Paul AK, Smith CM, Rahmatullah M, Nissapatorn V, Wilairatana P, et al., 'Opioid analgesia and opioid-Induced adverse effects: A review', Pharmaceuticals, 14 pp. 1-22. ISSN 1424-8247 (2021) [Substantial Review] DOI: 10.3390/ph14111091 [eCite] [Details] Co-authors: Paul AK | |
| 2020 | Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, et al., 'Dimethyl fumarate and its esters: a drug with broad clinical utility?', Pharmaceuticals, 13, (10) pp. 1-15. ISSN 1424-8247 (2020) [Substantial Review] DOI: 10.3390/ph13100306 [eCite] [Details] Citations: Scopus - 12Web of Science - 13 | |
| 2015 | Buyse GM, Gueven N, McDonald CM, 'Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy', European Neurological Review, 10, (2) ISSN 1758-3837 (2015) [Review Several Works] | |
| 2015 | Yin X, Guven N, Dietis N, 'Opioids in Depression: Not Quite There Yet', UK Journal of Pharmaceutical and Biosciences, 3, (1) pp. 12-17. ISSN 2347-9442 (2015) [Substantial Review] Co-authors: Yin X; Dietis N | |
| 2014 | Gueven N, 'Optic Neurodegeneration: Time to Act', Biology and Medicine, 1, (1) pp. 1-6. ISSN 0974-8369 (2014) [Substantial Review] DOI: 10.4172/0974-8369.S1-001 [eCite] [Details] Citations: Scopus - 1 | |
| 2013 | Gueven N, Faldu D, 'Therapeutic strategies for Leber's hereditary optic neuropathy: A current update', Intractable & Rare Diseases Research., 2, (4) pp. 130-135. ISSN 2186-3644 (2013) [Substantial Review] Co-authors: Faldu D | |
| 2013 | Guven N, Faldu D, 'Idebenone treatment in Leber's hereditary optic neuropathy: rationale and efficacy', Expert opinion on orphan drugs, 2, (4) pp. 130-135. ISSN 2167-8707 (2013) [Substantial Review] DOI: 10.1517/21678707.2013.772894 [eCite] [Details] Citations: Scopus - 6Web of Science - 4 Co-authors: Faldu D | |
| 2008 | Lavin MF, Gueven N, Grattan-Smith P, 'Defective responses to DNA single- and double-strand breaks in spinocerebellar ataxia', DNA Repair, 7 pp. 1061-1076. ISSN 1568-7864 (2008) [Substantial Review] DOI: 10.1016/j.dnarep.2008.03.008 [eCite] [Details] Citations: Scopus - 17Web of Science - 15 | |
| 2007 | Lavin MF, Guven N, Bottle S, Gatti RA, 'Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia', British Medical Bulletin, 81-82, (1) pp. 129-147. ISSN 0007-1420 (2007) [Substantial Review] DOI: 10.1093/bmb/ldm012 [eCite] [Details] Citations: Scopus - 116Web of Science - 93 | |
| 2005 | Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, et al., 'ATM signaling and genomic stability in response to DNA damage', Mutation Research - D N Aging, 569, (1-2) pp. 123-32. ISSN 0921-8734 (2005) [Substantial Review] | |
| 2004 | Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, et al., 'Functional consequences of sequence alterations in the ATM gene', D N A Repair, 3, (8-9) pp. 1197-205. ISSN 1568-7864 (2004) [Review Several Works] |
Conference Publication
(4 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2017 | Cui H, Zhang A, Geraghty DP, Nott L, Guven N, et al., 'Tumour expression of copper transporters in colorectal cancer patients', Proceedings of APSA-ASCEPT 2017, 5-8 Dec 2017, Brisbane, pp. 538. (2017) [Conference Extract] Co-authors: Geraghty DP | |
| 2016 | Cui H, Zhang A, Geraghty DP, Nott L, Guven N, et al., 'Targeting CTR1 to enhance the uptake and cytotoxicity of oxaliplatin in colorectal cancer cells', Proceedings of ASCEPT-APSA 2016, 27-30 Nov 2016, Melbourne, pp. 1. (2016) [Conference Extract] Co-authors: Geraghty DP | |
| 2014 | Cui H, Zhang A, Geraghty DP, Nott L, Guven N, et al., 'Expression of copper transporters in colorectal cancer cells and its relation to oxaliplatin', Proceedings of ASCEPT-MPGPCR 2017, 7-11 Dec 2014, Melbourne, pp. 1. (2014) [Conference Extract] Co-authors: Geraghty DP | |
| 2003 | Truman J-P, Gueven N, Lavin M, Leibel S, Kolesnick R, et al., 'Transcriptional down-regulation of Ataxia-Telangiectasia Mutated protein (ATM) radiosensitizes human prostate cancer cells', INIS Collection, 17-22 August 2003, Brisbane, Australia, pp. 100. (2003) [Refereed Conference Paper] |
Patent
(5 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2018 | Guven N, Smith J, Woolley KL, Nadikudi M, 'WO2018/191789 A1: Therapeutic compounds and methods' (2018) [Patent] Co-authors: Smith J; Woolley KL; Nadikudi M | |
| 2012 | Feurer A, Gueven N, Hoffman-Enger B, Erb M, Deppe H, et al., 'Benzoquinone Derivatives as Modulators of Mitochondrial Function' (2012) [Patent] | |
| 2012 | Feurer A, Hoffmann-Enger B, Deppe H, Soeberdt M, Gueven N, et al., 'Novel Benzoquinone Derivatives and Use Thereof as Modulators of Mitochondrial Function' (2012) [Patent] | |
| 2000 | Dittmann K, Guven N, Mayer C, Rodemann PH, 'Protection of cells in connection with treatment with chemical agents' (2000) [Patent] | |
| 1999 | Rodemann H, Dittmann K, Guven N, Mayer C, 'Peptide with radio protective effect' (1999) [Patent] |
Grants & Funding
Due to the applied nature of his research, Associate Prof Güven receives funding for his work mostly by charities, patient organisations and commercial entities.
Funding Summary
Number of grants
27
Total funding
Projects
- Funding
- Chiesi Australia Pty Ltd ($2,400)
- Scheme
- Consultancy
- Administered By
- University of Tasmania
- Research Team
- Guven N
- Year
- 2021
- Description
- In this proposal we aim to utilise our novel established agar assay to screen a unique library of 320 structurally diverse small molecule drugs that are currently clinically used for central nervous system (CNS) diseases, for their effect on the growth of medulloblastoma brain cancer cell lines. Drugs already in clinical use provide a considerable opportunity to rapidly re-purpose drugs for MB. Furthermore, this custom library only contains drugs that are in use for CNS diseases and are therefore BBB-permeable, a feature that is crucial for brain cancer.
- Funding
- Cancer Council of Tasmania ($14,828)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- Azimi I; Guven N
- Year
- 2021
- Description
- This application supports a valley of death project to generate the pre-clinical toxicity data that are required towards commercialisation of UTAS-derived novel drug candidates
- Funding
- National Foundation for Medical Research and Innovation ($144,300)
- Scheme
- Grant-Expression of Interest
- Administered By
- University of Tasmania
- Research Team
- Guven N; Smith JA; Ambrose M
- Period
- 2020 - 2021
- Description
- This project will assess the short-term toxicity of 12 test compounds for Martha Jane Medical.
- Funding
- Martha Jane Medical ($8,677)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Guven N; Jacobson GA
- Year
- 2019
- Description
- We will test an HDAC6 inhibitor in models of ALS. We will investigate the HDA6 inhibitor activity of novel compounds
- Funding
- FightMND ($997,046)
- Scheme
- Grant - Drug Development Grant
- Administered By
- University of Tasmania
- Research Team
- King AE; Cook AL; Guven N; Van Den Bosch L; Dickson TC; Blizzard C; Vickers JC; Smith JA; Alty JE; Leung JY; Perry SE
- Period
- 2019 - 2022
- Description
- There are no drugs that improve the outcomes following a stroke. We have recently identified idebenone as a neuroprotective agent during times of energy stress. This pilot project will investigate whether idebenone can be used to reduce the severity of stroke in a pre-clinical animal model.
- Funding
- Royal Hobart Hospital Research Foundation ($9,962)
- Scheme
- Grant-Incubator
- Administered By
- University of Tasmania
- Research Team
- Premilovac D; Sutherland BA; Howells DW; Guven N; Castley H
- Year
- 2019
- Description
- Cannabis and cannabis extracts have been reported to have beneficial applications to many indications including the management of seizures, pain, cancer and appetite amongst others. One problem has been the illicit nature of the material which results in lack of control of the dose and chemical profile of material which can be due to different plant varieties, growing conditions, extraction preparation and mode of delivery. This project aims to adopt a drug discovery approach to provide solid evidence for the effect of different cannabinoids by isolating the individual components for thorough evaluation of any therapeutical applications. In this way, clear dose dependant activity can be studied and protocols for the prescription of cannabinoids can be developed that are in-line with modern pharmaceutical procedures. This will also be the start point for the development of novel semi-synthetic cannabinoids that will allow us to develop structure activity relationships for different indications. This potentially extends the scope of the medicinal cannabis industry to be a raw material for the synthesis of active non-natural derivates similar to the semi-synthetic opiates.
- Funding
- Martha Jane Medical ($105,000)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Smith JA; Jacobson GA; Guven N; Bissember AC
- Period
- 2018 - 2021
- Funding
- University of Tasmania ($24,938)
- Scheme
- Grant- Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- Azimi I; Guven N; Dickinson JL
- Year
- 2018
- Description
- Checkpoint molecule blockade immunotherapy (e.g. PD-1 monoclonal antibody) has achieved unprecedented success in treating several types of cancer, and ITIM and ITSM signalling play a key role in these treatment approaches. The cancer immunotherapy market reached $16.9 billion in 2015 and is expected to grow to $75 billion by 2022 (GBI 2016). This has greatly improved patient outcomes, but the cost to a single patient can exceed $100,000. The research proposed here has the potential to discover many new drug targets. Importantly, the targets are short peptide sequences, which open the door to using small molecule compounds instead that can be produced and formulated at a significantly lower cost than protein-based therapies. This will benefit cancer patients by reducing the cost for treatment and simultaneously help UTAS enter the rapidly expanding cancer immunotherapy market.
- Funding
- University of Tasmania Foundation Inc ($36,155)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Guven N; Blackburn NR; Lyons AB
- Year
- 2017
- Description
- Industry interaction to develop Marinovas fucoidan extracts for gut health
- Funding
- Department of Industry, Innovation and Science ($50,000); Marinova Pty Ltd ($50,000)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Guven N; Eri RD; Ahuja KDK; Ball MJ; Ambrose M; Roddam LF; Zosky GR
- Year
- 2016
- Description
- We will test novel short chain quinones against idebenone and related compounds in a rat model of diabetic retinopathy.
- Funding
- Santhera Pharmaceuticals Holding AG ($75,174)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Guven N; Premilovac D; Foa LC
- Period
- 2016 - 2019
- Funding
- University of Tasmania ($14,673)
- Scheme
- Grant-Research Enhancement (REGS)
- Administered By
- University of Tasmania
- Research Team
- Premilovac D; Foa LC; Taylor BVM; Guven N
- Year
- 2016
- Description
- This project involves industry interaction to develop Marinova's fucoidan extract against cancer.
- Funding
- Marinova Pty Ltd ($54,917)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Guven N; Dietis ND; Davis E
- Period
- 2015 - 2016
- Description
- Industry interaction to test if Marinova's fucoidan extracts mobilise stem cells.
- Funding
- Marinova Pty Ltd ($27,048)
- Scheme
- Clinical Trial
- Administered By
- University of Tasmania
- Research Team
- Guven N; Eri RD; Ahuja KDK; Patel RP
- Year
- 2015
- Description
- This project represents industry interaction to develop Marinovas fucoidan extract for gut health.
- Funding
- Department of Industry, Science, Energy and Resources ($50,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Guven N; Davis E; Eri RD; Patel RP
- Year
- 2015
- Description
- The aim of our study is to assess the anticancer effect of our 10 novel opioid drugs in six different intestinal cancer cell lines and compare them with oxaliplatin and irinotecan. The particular objectives of the study are:1. To evaluate the effect of our novel drugs on intestinal cancer cell viability, growth, proliferation and ability to form colonies.2. To explore the molecular mechanisms of the anticancer activity of our novel drugs.
- Funding
- Cancer Council of Tasmania ($6,567)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dietis ND; Liu J; Holloway AF; Guven N
- Year
- 2015
- Description
- Sufficient cellular energy production is essential for normal vision, which is exemplified by Lebers Hereditary Optic Neuropathy (LHON). This disorder is a devastating disease that affects predominantly young men in their 20s to 30s. Affected individuals typically have normal vision, before in their 20s they irreversibly lose their vision. Currently, there is no treatment on the market to prevent or restore vision loss. However, several clinical trials in LHON and other mitochondrial optic neuropathy patients support a limited therapeutic benefit of short-chain quinone compounds. Based on previous in-depth experience with this class of compounds in vitro and in-vivo acquired in commercial and academic laboratories, the project proposes to discover and characterize novel quinone compounds with improved activity. This project is based on a rational medicinal-chemistry optimization program to improve the activity of known molecules and to provide a safe and cost-effective prevention and therapy option for optic neuropathy patients.
- Funding
- Rebecca L Cooper Medical Research Foundation ($6,900)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Guven N
- Year
- 2015
- Description
- This project aims to achieve the identification and evaluation of non-anticoagulant molecules of heparin that are responsible for the observed beneficial effects of heparin in patients with ulcerative colitis as well as to compare potential biomarkers in a preclinical muse model with ulcerative colitis patients.
- Funding
- Royal Hobart Hospital Research Foundation ($15,000)
- Scheme
- Grant-Clinical Research
- Administered By
- University of Tasmania
- Research Team
- Patel RP; Guven N; Eri RD; Bhatia R
- Year
- 2015
- Description
- Chemotherapy-induced neuropathy (CIN) is a dose-limiting side effect of chemotherapy treatment, causing irreversible disability in 40% of cancer survivors. CIN results from the loss or damage of neurons during chemotherapy. We have compelling evidence that the protein metallothionein promotes regeneration of peripheral nerves, and examine its therapeutic use in CIN.This project will create new knowledge in the area of chemotherapy induced neuropathy, and establish the suitability of trophic agents as disease-modifying agents for chemotherapy-induced neuropathy.
- Funding
- Royal Hobart Hospital Research Foundation ($21,739)
- Scheme
- Grant-Clinical Research
- Administered By
- University of Tasmania
- Research Team
- Taylor BVM; Landowski LM; West AK; Vickers JC; Foa LC; Guven N
- Year
- 2015
- Description
- This project is a literature overview on the comparison of the two benzoquinones idebenone and CoQ10, with regards to biological and therapeutic activity.
- Funding
- Santhera Pharmaceuticals Holding AG ($3,830)
- Scheme
- Consultancy
- Administered By
- University of Tasmania
- Research Team
- Guven N
- Year
- 2014
- Description
- Brown algal extracts, in particular those containing fucoidan have been shown to have potential applications in a number of health indications such as prediabetes, immunomodulation, cardiovascular disease, inflammation and gut health. With advances in technology, fucoidan extracts from brown seaweed can now be produced successfully on a commercial scale. These types of extracts are beginning to become more prevalent as ingredients in western dietary supplement markets. However, for the extracts to successfully enter this market, efficacy, safety and provenance must be proven to help gain acceptance. With this in mind, the objectives of this project include the following: to establish the efficacy of high purity fucoidan extract from Fucusvesiculosus in the treatment of ulcerative colitis in an animal model; and to compare the efficacy of the routes of administration of Fucusvesiculosus fucoidan in treating ulcerative colitis with particular reference to oral and intra-peritoneal dosages.
- Funding
- Marinova Pty Ltd ($2,810)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Peterson GM; Guven N; Patel RP
- Year
- 2013
- Description
- Most eye disorders are associated with mitochondrial dysfunction. Based on the mitochondria-protective drug idebenone, we will synthesize novel, improved neuroprotective compounds. These compounds will be tested in a microfluidics cell culture model of mechanical stress-induced neuro-degeneration to identify new treatments strategies against retinal degeneration.
- Funding
- Royal Hobart Hospital Research Foundation ($9,090)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- McCartney PJ; Guven N; Guijt RM; Smith JA
- Year
- 2013
- Funding
- The Cancer Council, Queensland ($160,000)
- Scheme
- Project
- Administered By
- Queensland Institute of Medical Research
- Research Team
- Lavin MF; Gueven N
- Year
- 2008
- Funding
- National Ataxia Foundation (NAF) / Friedreichs Ataxia Research Alliance (FARA), USA ($100,000)
- Scheme
- Kyle Bryant Translational Research Award
- Administered By
- Queensland Institute of Medical Research
- Research Team
- Gueven N; Pook M
- Year
- 2007
- Funding
- National Health and Medical Research Council ($466,500)
- Scheme
- Project
- Administered By
- Queensland Institute of Medical Research
- Research Team
- Lavin MF; Gueven N; Becherel O
- Period
- 2007 - 2009
- Funding
- National Health and Medical Research Council ($267,750)
- Scheme
- Project
- Administered By
- Queensland Institute of Medical Research
- Research Team
- Lavin MF; Gueven N
- Period
- 2005 - 2007
- Funding
- Queensland Cancer Fund ($140,000)
- Scheme
- Project
- Administered By
- Queensland Institute of Medical Research
- Research Team
- Lavin MF; Gueven N
- Period
- 2004 - 2005
Research Supervision
Associate Prof Güven supervises a number of PhD candidates as well as Master's of Pharmaceutical Sciences students at the University of Tasmania. The quality of his supervision is illustrated by the fact that one of his students was invited to present her results at a prestigious Gordon Conference and several students generated data that resulted in patent applications. He also trained numerous technical staff and actively mentors the junior colleagues within the School of Pharmacy and Pharmacology. He is involved in undergraduate teaching and regularly contributes to practicals and tutorials. The quality, impact and relevance of his undergraduate lectures have been acknowledged by colleagues, course co-ordinators and students.
Current
9
Completed
13
Current
| Degree | Title | Commenced |
|---|---|---|
| PhD | Efficacy of Short-Chain Quinones in Colitis: Future therapeutic options | 2016 |
| PhD | Investigating the Therapeutic Efficacy of Non-anticoagulant Fractions (Dp2 and Dp4) of Enoxaparin following Experimental Traumatic Brain Injury | 2017 |
| PhD | Development of Short-Chain Quinones | 2017 |
| PhD | Identification and Characterisation of Novel Therapeutic Targets for the Control of Brain Cancers | 2019 |
| PhD | Cellular and Molecular Events in Progression of Medulloblastoma | 2019 |
| PhD | Isolation of Plant Secondary Metabolites of Taxonomic and Therapeutic Significance | 2020 |
| PhD | Effects of Insulin on Muscle Performance, Exercise Recovery and the Interrelationship with Beta2-Agonists Drugs | 2020 |
| PhD | Developing Drugs to Protect Neuronal Connections in Neurodegenerative Diseases | 2020 |
| PhD | Identification of the Cyto-protective Mode of Action of Short Chain Quinones (SCQ's) | 2020 |
Completed
| Degree | Title | Completed |
|---|---|---|
| PhD | Pharmaceutical Opioid Use and Cognitive and Behavioural Harms Among People who Experience Chronic Non-cancer Pain Candidate: Jane Susanna Akhurst | 2021 |
| PhD | Mitochondrial Therapy Against Diabetic Retinopathy Candidate: Abraham Ojochenemi Daniel | 2020 |
| PhD | Dissecting the Pharmaceutical and Immunological Aspects of Myrmecia pilosula (Jack Jumper) Ant Venom Immunotherapy Candidate: Stephanus Troy Wanandy | 2019 |
| PhD | Investigation on the Utilization of Beneficial Microbes in Modulating the Gut Microbiota and Metabolic Profiles in Ageing Candidate: Ravichandra Vemuri | 2019 |
| PhD | Novel Short-Chain Quinones Against Mitochondrial Dysfunction Candidate: Monila Nadikudi | 2019 |
| PhD | The Mutagenic Activity of Oxazolopyridine Compounds Candidate: Hsien Hooi Lee | 2018 |
| PhD | The Role of Copper Transporters in In Vitro Cytotoxicity of Oxaliplatin and Their Expression in Colorectal Cancer Candidate: Haigang Cui | 2018 |
| PhD | Strategies to Reduce the Impact of Opioid-Induced Adverse Effects Candidate: Alok Kumar Paul | 2018 |
| PhD | Pharmacological Modulation of Mood, Behaviour and Cognition Candidate: Xin Yin | 2018 |
| PhD | Synthesis of New Derivatives Targeting Mitochondrial Dysfunction Candidate: Krystel Lee Woolley | 2018 |
| PhD | Towards Understanding the Mechanism of Clioquinol Neurotoxicity Candidate: Jamuna Chhetri | 2017 |
| PhD | Bioprocess Monitoring Using Sequential Injection Capillary Electrophoresis Candidate: Ala Abdul Kareem Ahmad Alhusban | 2016 |
| PhD | Heparins and Fucoidans: Future therapeutic options for ulcerative colitis Candidate: Qi Ying Lean | 2016 |